187 related articles for article (PubMed ID: 15552803)
1. First-line chemotherapy in metastatic small-cell lung cancer (SCLC).
Wolf M; Tebbe S; Fink T
Lung Cancer; 2004 Aug; 45 Suppl 2():S223-34. PubMed ID: 15552803
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
3. Small cell lung cancer: strategies to optimize chemotherapy response.
Psyrri A; Murren J
Cancer J; 2001; 7 Suppl 1():S28-34. PubMed ID: 11504283
[TBL] [Abstract][Full Text] [Related]
4. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
5. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
6. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
Bozcuk H; Artac M; Ozdogan M; Savas B
Cancer; 2005 Dec; 104(12):2650-7. PubMed ID: 16284984
[TBL] [Abstract][Full Text] [Related]
7. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
8. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
9. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
10. Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient.
Kaira K; Ishizuka T; Yanagitani N; Sunaga N; Hisada T; Mori M
Gan To Kagaku Ryoho; 2007 Feb; 34(2):225-7. PubMed ID: 17301532
[TBL] [Abstract][Full Text] [Related]
11. [Dose intensity of chemotherapy in small-cell lung carcinoma].
Borg C; Ligneau B; Trillet-Lenoir V
Bull Cancer; 2001 Sep; 88(9):863-70. PubMed ID: 11604359
[TBL] [Abstract][Full Text] [Related]
12. Topotecan in the treatment of recurrent small cell lung cancer: an update.
Ardizzoni A
Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
[TBL] [Abstract][Full Text] [Related]
13. [Recent development in the treatment of lung cancer: from the point of view of the medical oncologist].
Joss R
Schweiz Med Wochenschr; 2000 May; 130(19):684-90. PubMed ID: 10846762
[TBL] [Abstract][Full Text] [Related]
14. Treatment of brain metastases from lung cancer: chemotherapy.
Schuette W
Lung Cancer; 2004 Aug; 45 Suppl 2():S253-7. PubMed ID: 15552807
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy in lung carcinoma].
Egger T; Cerny T
Ther Umsch; 1994 Apr; 51(4):267-71. PubMed ID: 7514814
[TBL] [Abstract][Full Text] [Related]
17. Second-line for small cell lung cancer: how-to-do-it?
Postmus PE
Lung Cancer; 2005 May; 48(2):263-5. PubMed ID: 15829327
[No Abstract] [Full Text] [Related]
18. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
[TBL] [Abstract][Full Text] [Related]
19. The importance of drug diversity in the treatment of small cell lung cancer.
Murray N
Semin Oncol; 2001 Apr; 28(2 Suppl 4):38-42. PubMed ID: 11479896
[TBL] [Abstract][Full Text] [Related]
20. [The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer].
Bozóky G; Ruby E; Góhér I; Gábor G; Mohos A; Lengyel M
Orv Hetil; 2005 Jul; 146(27):1433-8. PubMed ID: 16089103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
